CV Science

Tony jourdan PhD

Course and current status

2017-present                Research associate, Inserm U1231, team Pathophysiology of Dyslipidemia, Dijon, fr

2016-2017                   Research Fellow, Laboratory of physiologic studies, NIAAA DICBR, NIH, Rockville, MD.

Mentor: George Kunos, M.D., Ph.D.

2011-2015                   Postdoctoral Fellow, Laboratory of physiologic studies, NIAAA DICBR, NIH, Rockville, MD.

Mentor: George Kunos, M.D., Ph.D.

2007-2010                   Research Associate, Ph.D. program in Food Sciences (specialty Nutrition). Resarch Group physiopathology of dyslipidemia, INSERM U866 “Lipids-Nutrition-Cancer”, Faculty of sciences, Dijon, France.

                                    Mentors: Pascal Degrace, Ph.D.

Scientific summary

I started my journey as a scientist at the University of Burgundy in Dijon (France) with a Master’s degree in cellular biology and physiology. I then pursued a PhD internship under the supervision of Pr. Pascal Degrace within Pr. Bruno Vergès lab (INSERM U866, team PADYS). I mostly worked on the impact of the endocannabinoid system on the development of insulin resistance and NASH. After graduating in 2010, I had the chance to join one of the world leading group in the field of endocannabinoids and metabolic diseases at the National Institutes of Health. The laboratory of physiologic studies led by the Pr. George Kunos (National Institute of Alcohol Abuse and Alcoholism, NIAAA) was among the first one to determine a critical role for the peripherally-expressed cannabinoid 1 receptor (CB1R) in obesity and its metabolic sequelae. From April 2011 to November 2017, I worked on the impact of macrophages-expressed CB1R on the development of type-2 diabetes and its renal complication as well as the development of hepatic insulin resistance. In December 2017, I moved back to France as a “Chargé de Recherche” INSERM within the INSERM center Lipids, Nutrition, Cancer LNC U1231 in Dijon, France.  My goal there is to develop a new research program aiming at unraveling the molecular mechanisms underlying the immunometabolic effects of macrophages-expressed CB1R during the development of diabetic dyslipidemia